Helix BioPharma Corp. (TSE:HBP - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as C$1.60 and last traded at C$1.60, with a volume of 876 shares traded. The stock had previously closed at C$1.51.
Helix BioPharma Stock Performance
The company has a fifty day simple moving average of C$1.25 and a two-hundred day simple moving average of C$1.01. The company has a market capitalization of C$118.39 million, a price-to-earnings ratio of -1.50 and a beta of -0.45.
About Helix BioPharma
(
Get Free Report)
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.
Further Reading
Before you consider Helix BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.
While Helix BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
